Reuters

01 Jun 2026, 14:30 UTC · 1h ago

Apotex Health seeks to raise up to C$1.2 billion, potentially reviving Toronto IPO market

Read original · https://www.reuters.com/legal/transactional/apotex-health-seeks-raise-up-c12-billion-potentially-reviving-toronto-ipo-market-2026-06-01/

Search tags

Story key points

2 claims · impact-rated

What matters in this story

1
Apotex Health is seeking to raise up to C$1.2 billion ($868.06 million) via an IPO on the Toronto Stock Exchange. — A large-scale listing introduces significant new equity and liquidity into the Canadian healthcare sector.
+0.30
2
The Apotex IPO has the potential to revive Canada's currently subdued IPO market. — A successful high-profile IPO can improve investor sentiment and signal a reopening for other companies to go public.
+0.20

Ticker attribution

Model heads

Sentiment in this article

No ticker sentiment head found.

Relationships in this article

No ticker relationship head found.

Early access

You’re reading about it. Someone else is already positioned.

News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.

Browse live screenings

6 related stories

Globe News Wire
6h ago
Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases
- healthcare
- pharmaceuticals
Read

Apotex Health seeks to raise up to C$1.2 billion, potentially revivin… · News Impact Screener

Apotex Health seeks to raise up to C$1.2 billion, potentially reviving Toronto IPO market

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Apotex Health seeks to raise up to C$1.2 billion, potentially reviving Toronto IPO market

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs

Apotex Health seeks to raise up to C$1.2 billion, potentially reviving Toronto IPO market

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Apotex Health seeks to raise up to C$1.2 billion, potentially reviving Toronto IPO market

What matters in this story

Sentiment in this article

Relationships in this article

You’re reading about it. Someone else is already positioned.

Next reads from the same story arc

Aplagon Announces Review Publication on APAC, a First-in-Class Dual-Action Antithrombotic to Treat Unmet Clinical Needs in Thromboinflammatory Diseases

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

UCB and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

Idorsia reports new positive results with its breakthrough C. difficile vaccine – underscoring the unique potential of its glycan technology

Teva Pharmaceutical Industries Just Pulled Off One of Pharma's Most Impressive Comebacks

Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs